Actavis is delighted to introduce Atorvastatin to its portfolio of products launched on day one of patent expiry. The patent expiry of Atorvastatin is set to create one of the biggest

Actavis is delighted to announce the launch of Candesartan. Only four weeks after the launch of Quetiapine, it brings Actavis’ total of day-one patent expiries in 2012 to eight, and new

Watson to Acquire Actavis Group for EUR 4.25 Billion · Creates 3rd